Chongqing Zhifei Bio Products (300122) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.048x

Based on the latest financial reports, Chongqing Zhifei Bio Products (300122) has a cash flow conversion efficiency ratio of 0.048x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥1.42 Billion ≈ $207.88 Million USD) by net assets (CN¥29.61 Billion ≈ $4.33 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 300122 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.

Chongqing Zhifei Bio Products - Cash Flow Conversion Efficiency Trend (2007–2025)

This chart illustrates how Chongqing Zhifei Bio Products's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Chongqing Zhifei Bio Products Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Chongqing Zhifei Bio Products ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Amorepacific Corp. (New)
KO:090430
-0.005x
FLSmidth & Co.
CO:FLS
0.000x
Bidvest Group Ltd
JSE:BVT
0.172x
Schibsted ASA B
OL:SCHB
0.011x
BRITISH LAND ADR/1 LS-25
F:BLDA
N/A
Uxi Unicomp Technology Co. Ltd. A
SHG:688531
N/A
China Vanke Co Ltd Class A
SHE:000002
-0.006x
Keda Clean Energy Co Ltd
SHG:600499
0.088x

Annual Cash Flow Conversion Efficiency for Chongqing Zhifei Bio Products (2007–2025)

The table below shows the annual cash flow conversion efficiency of Chongqing Zhifei Bio Products from 2007 to 2025. For the full company profile with market capitalisation and key ratios, see 300122 stock market capitalisation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 CN¥16.11 Billion
≈ $2.36 Billion
CN¥5.17 Billion
≈ $756.14 Million
0.321x +324.09%
2024-12-31 CN¥30.83 Billion
≈ $4.51 Billion
CN¥-4.41 Billion
≈ $-645.91 Million
-0.143x -150.14%
2023-12-31 CN¥31.51 Billion
≈ $4.61 Billion
CN¥9.00 Billion
≈ $1.32 Billion
0.286x +247.93%
2022-12-31 CN¥24.24 Billion
≈ $3.55 Billion
CN¥1.99 Billion
≈ $291.06 Million
0.082x -82.97%
2021-12-31 CN¥17.66 Billion
≈ $2.58 Billion
CN¥8.51 Billion
≈ $1.24 Billion
0.482x +13.66%
2020-12-31 CN¥8.25 Billion
≈ $1.21 Billion
CN¥3.50 Billion
≈ $511.68 Million
0.424x +78.23%
2019-12-31 CN¥5.75 Billion
≈ $841.02 Million
CN¥1.37 Billion
≈ $200.03 Million
0.238x +69.81%
2018-12-31 CN¥4.18 Billion
≈ $611.80 Million
CN¥585.59 Million
≈ $85.69 Million
0.140x +102.07%
2017-12-31 CN¥2.94 Billion
≈ $429.85 Million
CN¥203.61 Million
≈ $29.79 Million
0.069x +94.27%
2016-12-31 CN¥2.52 Billion
≈ $368.94 Million
CN¥89.95 Million
≈ $13.16 Million
0.036x -60.57%
2015-12-31 CN¥2.47 Billion
≈ $361.33 Million
CN¥223.45 Million
≈ $32.70 Million
0.090x +37.81%
2014-12-31 CN¥2.46 Billion
≈ $359.64 Million
CN¥161.39 Million
≈ $23.62 Million
0.066x -29.19%
2013-12-31 CN¥2.39 Billion
≈ $349.62 Million
CN¥221.58 Million
≈ $32.42 Million
0.093x +94.94%
2012-12-31 CN¥2.37 Billion
≈ $347.24 Million
CN¥112.89 Million
≈ $16.52 Million
0.048x -51.45%
2011-12-31 CN¥2.26 Billion
≈ $330.43 Million
CN¥221.25 Million
≈ $32.38 Million
0.098x +287.24%
2010-12-31 CN¥2.14 Billion
≈ $313.40 Million
CN¥54.19 Million
≈ $7.93 Million
0.025x -94.57%
2009-12-31 CN¥451.69 Million
≈ $66.10 Million
CN¥210.61 Million
≈ $30.82 Million
0.466x -12.05%
2008-12-31 CN¥267.06 Million
≈ $39.08 Million
CN¥141.58 Million
≈ $20.72 Million
0.530x -10.72%
2007-12-31 CN¥188.03 Million
≈ $27.52 Million
CN¥111.66 Million
≈ $16.34 Million
0.594x --

About Chongqing Zhifei Bio Products

SHE:300122 China Biotechnology
Market Cap
$4.37 Billion
CN¥29.87 Billion CNY
Market Cap Rank
#3959 Global
#615 in China
Share Price
CN¥12.48
Change (1 day)
+0.97%
52-Week Range
CN¥11.93 - CN¥25.06
All Time High
CN¥11976.62
About

Chongqing Zhifei Biological Products Co., Ltd., a biopharmaceutical company, engages in the research and development, production, sale, and distribution of vaccine and biological products in China. The company offers recombinant COVID-19 vaccine; recombinant mycobacterium tuberculosis fusion protein products; group A and C meningococcal polysaccharide vaccine; ACYW135 meningococcal polysaccharide… Read more